Nano-X Imaging Ltd. (NASDAQ: NNOX) announced on September 8, 2026, that its U.S. subsidiary, Nanox Impact Inc., has entered into a distribution agreement with Associated X-Ray Imaging Corp. to support the deployment of its Nanox.ARC system across New England. The agreement enables Associated X-Ray Imaging to market, distribute, and support the FDA-cleared, multisource 3D digital tomosynthesis system, leveraging its regional customer relationships and service infrastructure.
This expansion is part of Nanox's strategy to grow its U.S. channel partner network and increase access to the Nanox.ARC in outpatient and community-based clinical settings across targeted markets. The Nanox.ARC is designed to be a cost-effective, 3D multi-source digital tomosynthesis imaging system that aims to bring advanced imaging capabilities beyond traditional hospital settings.
The importance of this distribution agreement lies in its potential to broaden the availability of affordable imaging technology, which is a key component of Nanox's mission to drive the world's transition to preventive healthcare. By partnering with a regional distributor like Associated X-Ray Imaging, Nanox can better penetrate the New England market, where there is a growing demand for accessible diagnostic tools that can detect diseases earlier.
Nanox's integrated platform includes the Nanox.ARC, Nanox.AI algorithms for augmenting CT imaging interpretation, Nanox.CLOUD for secure data management, Nanox.MARKETPLACE and USARAD Holdings for remote radiology services, and Nanox Health IT for workflow solutions. This ecosystem is designed to lower barriers to adoption and improve utilization of imaging services, ultimately aiming to enhance clinical efficiency and patient outcomes.
The move comes at a time when the healthcare industry is increasingly focusing on preventive care and early detection. The Nanox.ARC's potential to provide affordable 3D imaging in community settings could play a significant role in identifying chronic diseases at earlier, more treatable stages. This distribution agreement is a strategic step for Nanox to expand its footprint in the United States, following its FDA clearance and initial commercial deployments.
For more details on the original announcement, visit https://nnw.fm/ChGtd. The latest news and updates regarding NNOX are available in the company's newsroom at https://ibn.fm/NNOX.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's filings with the SEC. Investors should not place undue reliance on these statements, as actual results may differ materially.
